Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial

NCT03676504 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT03676504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03676504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial
Lead sponsor
University Hospital Heidelberg
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 7, 2018
Completion date
December 31, 2027
Enrollment
68 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult, acute lymphoblastic leukemia, pediatric, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma